Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.
Sugimoto A, Kaneda H, Yoshimoto N, Nagata K, Fujii T, Michimoto K, Ueno S, Kamimori T, Ishii Y, Sakagami M, Inokuchi H, Shibuya K, Mizutani M, Nagamine H, Nakahama K, Matsumoto Y, Tani Y, Sawa K, Kawaguchi T.
Sugimoto A, et al. Among authors: sakagami m.
Sci Rep. 2024 Aug 23;14(1):19596. doi: 10.1038/s41598-024-70214-y.
Sci Rep. 2024.
PMID: 39179598
Free PMC article.